NEWS
International Affairs
- Publish Date：2025-09-30
NYCU Partners with TVGH and Japan’s NCCH to Establish Asia-Pacific Cancer Research Network
(Photo credit: TVGH)
Edited by Chance Lai
______
______
In a landmark move toward global cancer collaboration, National Yang Ming Chiao Tung University (NYCU), Taipei Veterans General Hospital (TVGH), and Japan’s National Cancer Center Hospital (NCCH) signed a Memorandum of Understanding (MOU) on September 26, pledging to advance cross-border research in cancer diagnostics, treatment, genomic medicine, and medical personnel exchange.
The agreement, signed by NYCU President Chi-Hung Lin, TVGH Superintendent Wei-Ming Chen, and NCCH Director Yasuyuki Seto, aims to establish an Asia-Pacific cancer research network and usher in a new era of precision oncology through transnational collaboration.
Engineering Meets Medicine: NYCU’s Unique Role in Driving Cancer Innovation
As the only university in Taiwan that integrates engineering and medicine, NYCU brings a unique edge to cancer research through its pioneering work in biomedical engineering, digital medicine, and AI-assisted diagnostics.
“Our university campus is physically interconnected with TVGH, enabling close collaboration between research and clinical application,” said President Lin. “We have invested significantly in the emerging discipline of engineering medicine, and we believe that integrating NYCU’s technological expertise with the clinical capabilities of TVGH and the international resources of NCCH will accelerate impactful cancer solutions.”
Japan’s Premier Cancer Institution Enters Trilateral Alliance
Japan’s National Cancer Center (NCC) is the nation’s leading cancer institution, operating the most extensive next-generation sequencing (NGS) database and a robust clinical trial infrastructure. Its affiliated hospital, NCCH, is globally recognized for advanced cancer care across breast, gastrointestinal, and respiratory tumors, and is home to the world’s only vertical-type Boron Neutron Capture Therapy (BNCT) facility.
“This MOU marks a new chapter in trilateral cooperation,” said NCCH Director Seto. “Over the next five years, we will work together on personnel exchange, research training, knowledge sharing, and international trials. Together, we hope to advance global cancer care and research.”
The agreement, signed by NYCU President Chi-Hung Lin, TVGH Superintendent Wei-Ming Chen, and NCCH Director Yasuyuki Seto, aims to establish an Asia-Pacific cancer research network and usher in a new era of precision oncology through transnational collaboration.
Engineering Meets Medicine: NYCU’s Unique Role in Driving Cancer Innovation
As the only university in Taiwan that integrates engineering and medicine, NYCU brings a unique edge to cancer research through its pioneering work in biomedical engineering, digital medicine, and AI-assisted diagnostics.
“Our university campus is physically interconnected with TVGH, enabling close collaboration between research and clinical application,” said President Lin. “We have invested significantly in the emerging discipline of engineering medicine, and we believe that integrating NYCU’s technological expertise with the clinical capabilities of TVGH and the international resources of NCCH will accelerate impactful cancer solutions.”
Japan’s Premier Cancer Institution Enters Trilateral Alliance
Japan’s National Cancer Center (NCC) is the nation’s leading cancer institution, operating the most extensive next-generation sequencing (NGS) database and a robust clinical trial infrastructure. Its affiliated hospital, NCCH, is globally recognized for advanced cancer care across breast, gastrointestinal, and respiratory tumors, and is home to the world’s only vertical-type Boron Neutron Capture Therapy (BNCT) facility.
“This MOU marks a new chapter in trilateral cooperation,” said NCCH Director Seto. “Over the next five years, we will work together on personnel exchange, research training, knowledge sharing, and international trials. Together, we hope to advance global cancer care and research.”
Advancing Clinical Innovation and Global Health
TVGH Superintendent Chen emphasized the urgent need for global partnerships in the fight against cancer: “As one of the most pressing public health challenges worldwide, cancer demands deep collaboration. TVGH has made strides in heavy particle therapy, BNCT, and precision surgery, and this alliance will expand both the depth and reach of our clinical trials—ultimately delivering advanced treatment to more patients.”
According to the MOU, the three institutions will focus on:
- Expanding international clinical trials and patient recruitment
- Building a shared NGS database and outcome analysis platform
- Co-hosting academic conferences on oncology and precision medicine
- Exchanging researchers, clinicians, and students across borders
- Promoting open data and regional collaboration across the Asia-Pacific
This partnership represents more than just a formal agreement—it is a shared commitment to improving lives through innovation and collaboration.
As the collaboration unfolds, NYCU will continue to serve as a critical bridge between academic research and medical practice. With its interdisciplinary strengths and international outlook, the university aims to shape the future of global healthcare.
Director Yasuyuki Seto (right) noted that the signing of the MOU will pave the way for broader collaboration, with all three parties working together to advance cancer research and benefit patients worldwide. (Photo credit: TVGH)
As the collaboration unfolds, NYCU will continue to serve as a critical bridge between academic research and medical practice. With its interdisciplinary strengths and international outlook, the university aims to shape the future of global healthcare.
Director Yasuyuki Seto (right) noted that the signing of the MOU will pave the way for broader collaboration, with all three parties working together to advance cancer research and benefit patients worldwide. (Photo credit: TVGH)Related Image(s)：
